E7050 + Cetuximab
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Conditions
Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Trial Timeline
Sep 19, 2011 → Sep 4, 2017
NCT ID
NCT01332266About E7050 + Cetuximab
E7050 + Cetuximab is a phase 1/2 stage product being developed by Eisai for Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck. The current trial status is completed. This product is registered under clinical trial identifier NCT01332266. Target conditions include Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01332266 | Phase 1/2 | Completed |
Competing Products
16 competing products in Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck